MCID: PYR010
MIFTS: 53

Peyronie's Disease malady

Categories: Rare diseases, Reproductive diseases

Aliases & Classifications for Peyronie's Disease

Aliases & Descriptions for Peyronie's Disease:

Name: Peyronie's Disease 39 12 14
Peyronie Disease 12 50 52 69
Balanitis Xerotica Obliterans 69
Induratio Penis Plastica 12
Peyronie's Fibromatosis 12
Peyronies Disease 39
Penile Induration 42
Penile Curvature 50

Classifications:



External Ids:

Disease Ontology 12 DOID:8616
ICD10 33 N48.6
ICD9CM 35 607.85
MeSH 42 D010411
NCIt 47 C3316
UMLS 69 C0030848

Summaries for Peyronie's Disease

NIH Rare Diseases : 50 peyronie disease is a connective tissue disorder characterized by a plaque, or hard lump, that forms within the penis. affected individuals may experience painful, curved erections which can make make normal sexual intercourse impossible. symptoms may appear suddenly or develop gradually. while the painful erections for most men resolve over time, the scar tissue and curvature may remain. some cases appear to resolve spontaneously. the exact cause of peyronie's disease is not known. last updated: 11/23/2011

MalaCards based summary : Peyronie's Disease, also known as peyronie disease, is related to dupuytren contracture dupuytren contracture 1, included and ledderhose disease, and has symptoms including abnormality of the skeletal system, abnormality of the genitourinary system and penile edema. An important gene associated with Peyronie's Disease is IFNA2 (Interferon Alpha 2), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Sevelamer and Chelating Agents have been mentioned in the context of this disorder. Affiliated tissues include small intestine, endothelial and testes, and related phenotypes are cellular and craniofacial

Wikipedia : 71 Peyronie\'s disease or Peyronie disease (/peɪroʊˈniː/), also known as induratio penis plastica (IPP)... more...

Related Diseases for Peyronie's Disease

Diseases related to Peyronie's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 26)
id Related Disease Score Top Affiliating Genes
1 dupuytren contracture dupuytren contracture 1, included 10.8
2 ledderhose disease 10.8
3 hypospadias 10.2
4 thalassemia minor 10.1 TGFB2 TGFB3
5 legionaire disease 10.1 TGFB2 TGFB3
6 geleophysic dysplasia 2 10.1 TGFB1 TGFB2
7 speech and communication disorders 10.0 SMAD3 TGFB1 TGFB3
8 chronic diarrhea due to guanylate cyclase 2c overactivity 10.0 DCN NOS2
9 discharging ear 10.0 TGFB1 TGFB2 TGFB3
10 mixed hepatoblastoma 10.0 IFNA2 TGFB1
11 intellectual developmental disorder with persistence of fetal hemoglobin 10.0 SMAD3 TGFB2 TGFB3
12 hereditary night blindness 10.0 DCN SMAD3 TGFB1
13 renal tubular transport disease 10.0 TGFB2 TGFB3
14 tmem231-related meckel syndrome 10.0 SMAD3 TGFB2 TGFB3
15 pulmonary valve insufficiency 9.9 SMAD3 SMAD7 TGFB1
16 acute necrotizing encephalitis 9.9 SMAD3 SMAD7 TGFB1
17 albright's hereditary osteodystrophy 9.9 SMAD3 SMAD7 TGFB3
18 hemorrhagic cystitis 9.9 SMAD3 SMAD7 TGFB1
19 endemic typhus 9.9 SMAD3 TGFB1 TGFB2 TGFB3
20 leber congenital amaurosis 9.8 SMAD3 SMAD7 TGFB1 TGFB3
21 neuroectodermal endocrine syndrome 9.8 DCN SMAD3 SMAD7 TGFB1
22 pulmonary edema 9.8
23 priapism 9.8
24 vibratory urticaria 9.7 IFNA2 PDE5A SMAD3 TGFB1 TGFB3
25 colorectal cancer 9.3 IFNA2 NOS2 SMAD3 SMAD7 TGFB1 TGFB2
26 lubani-al saleh-teebi syndrome 8.7 ACTG2 DCN IFNA2 NOS2 PDE5A SMAD3

Comorbidity relations with Peyronie's Disease via Phenotypic Disease Network (PDN):


Bladder Neck Obstruction Prostatic Hypertrophy
Urethral Stricture

Graphical network of the top 20 diseases related to Peyronie's Disease:



Diseases related to Peyronie's Disease

Symptoms & Phenotypes for Peyronie's Disease

Human phenotypes related to Peyronie's Disease:

32
id Description HPO Frequency HPO Source Accession
1 abnormality of the skeletal system 32 HP:0000924
2 abnormality of the genitourinary system 32 HP:0000119

UMLS symptoms related to Peyronie's Disease:


penile edema

MGI Mouse Phenotypes related to Peyronie's Disease:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.04 DCN NOS2 SMAD3 SMAD7 TGFB1 TGFB2
2 craniofacial MP:0005382 10.02 DCN NOS2 SMAD3 SMAD7 TGFB1 TGFB2
3 digestive/alimentary MP:0005381 10 DCN NOS2 SMAD3 SMAD7 TGFB1 TGFB2
4 hematopoietic system MP:0005397 9.95 TGFB2 TGFB3 DCN NOS2 SMAD3 SMAD7
5 endocrine/exocrine gland MP:0005379 9.91 DCN NOS2 SMAD3 SMAD7 TGFB1 TGFB2
6 immune system MP:0005387 9.91 DCN NOS2 SMAD3 SMAD7 TGFB1 TGFB2
7 reproductive system MP:0005389 9.73 DCN NOS2 SMAD3 SMAD7 TGFB1 TGFB2
8 renal/urinary system MP:0005367 9.72 DCN NOS2 SMAD3 TGFB1 TGFB2
9 respiratory system MP:0005388 9.55 DCN NOS2 TGFB1 TGFB2 TGFB3
10 skeleton MP:0005390 9.43 TGFB1 TGFB2 DCN NOS2 SMAD3 TGFB3
11 vision/eye MP:0005391 9.1 DCN NOS2 SMAD3 TGFB1 TGFB2 TGFB3

Drugs & Therapeutics for Peyronie's Disease

Drugs for Peyronie's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevelamer Approved Phase 3 52757-95-6, 152751-57-0 3085017
2 Chelating Agents Phase 3
3
Acetylcholine Approved Phase 2 51-84-3 187
4
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
5 abobotulinumtoxinA Phase 2
6 Botulinum Toxins Phase 2
7 Botulinum Toxins, Type A Phase 2
8 Cholinergic Agents Phase 2
9 incobotulinumtoxinA Phase 2
10 Neuromuscular Agents Phase 2
11 Neurotransmitter Agents Phase 2
12 onabotulinumtoxinA Phase 2
13 Peripheral Nervous System Agents Phase 2
14 Pharmaceutical Solutions Phase 2
15 Anesthetics Phase 2
16 Anesthetics, Local Phase 2
17 Anti-Arrhythmia Agents Phase 2
18 Central Nervous System Depressants Phase 2
19 Diuretics, Potassium Sparing Phase 2
20 Sodium Channel Blockers Phase 2
21
Methyltestosterone Approved Phase 1 58-18-4 6010
22
Testosterone Approved, Investigational Phase 1 58-22-0 6013
23
Ergocalciferol Approved, Nutraceutical Phase 1 50-14-6 5280793
24
Vitamin E Approved, Nutraceutical, Vet_approved Phase 1 59-02-9 14985
25 Anabolic Agents Phase 1
26 Androgens Phase 1
27 Antineoplastic Agents, Hormonal Phase 1
28 Antioxidants Phase 1
29 Bone Density Conservation Agents Phase 1
30 Ergocalciferols Phase 1
31 Hormone Antagonists Phase 1
32 Hormones Phase 1
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1
34 Micronutrients Phase 1
35 Protective Agents Phase 1
36 Testosterone 17 beta-cypionate Phase 1
37
Testosterone enanthate Phase 1 315-37-7 9416
38 Testosterone undecanoate Phase 1
39 Tocopherols Phase 1
40 Tocotrienols Phase 1
41 Trace Elements Phase 1
42 vitamin d Phase 1
43 Vitamins Phase 1
44 Calciferol Nutraceutical Phase 1
45 Tocopherol Nutraceutical Phase 1
46 Tocotrienol Nutraceutical Phase 1
47 Vitamin D2 Nutraceutical Phase 1
48 Phosphodiesterase 5 Inhibitors
49 Mitogens

Interventional clinical trials:

(show all 20)
id Name Status NCT ID Phase
1 Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease Active, not recruiting NCT02298829 Phase 4
2 A Study of AA4500 in Men With Peyronie's Disease Completed NCT01243411 Phase 3
3 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01685437 Phase 3
4 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221597 Phase 3
5 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221623 Phase 3
6 An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease Completed NCT02267460 Phase 3
7 A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis Terminated NCT00833768 Phase 3
8 Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010) Unknown status NCT01184586 Phase 2
9 The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease Completed NCT00755222 Phase 2
10 Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease Completed NCT01430169 Phase 2
11 H-22411: BOTOX® for Peyronie's Disease Recruiting NCT00812838 Phase 2
12 Clostridium Histolyticum Collagenase Injection for Urethral Disease Not yet recruiting NCT02948842 Phase 2
13 Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease Unknown status NCT01578473 Phase 1
14 Peyronie's Disease Treatment Protocol Completed NCT02072018 Phase 1
15 Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD Completed NCT02395029 Phase 1
16 Management of Peyronie's Disease With Adipose Tissue Stem Cell Unknown status NCT02414308
17 Efficacy of Extracorporal Shock Wave Therapy in Patient With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome Unknown status NCT01714830
18 Pregnant Women With a Breast Cancer Diagnosed Between 2000 and 2014 Unknown status NCT01503034
19 Change in Penile Length Following Bilateral Nerve-Sparing Radical Prostatectomy Completed NCT00800813
20 Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions Recruiting NCT01953523

Search NIH Clinical Center for Peyronie's Disease

Cochrane evidence based reviews: penile induration

Genetic Tests for Peyronie's Disease

Anatomical Context for Peyronie's Disease

MalaCards organs/tissues related to Peyronie's Disease:

39
Small Intestine, Endothelial, Testes, Monocytes, Bone, Prostate

Publications for Peyronie's Disease

Articles related to Peyronie's Disease:

(show top 50) (show all 624)
id Title Authors Year
1
Response and Rebuttal to Letter to the Editor: Evidence-Based Management Guidelines on Peyronie's Disease. ( 28065353 )
2017
2
Moving from Consensus- to Evidence-Based Clinical Practice Guidelines for Peyronie's Disease. ( 28065352 )
2017
3
Intralesional Injection of Hyaluronic Acid in Patients Affected With Peyronie's Disease: Preliminary Results From a Prospective, Multicenter, Pilot Study. ( 26984291 )
2016
4
Professor Wayne J.G. Hellstrom: incidence of Peyronie's disease. ( 26904421 )
2016
5
Re: An Analysis of Case Logs from American Urologists in the Treatment of Peyronie's Disease. ( 27751484 )
2016
6
Re: Use of a Lyophilized Bovine Pericardium Graft to Repair Tunical Defect in Patients with Peyronie's Disease: Experience in a Clinical Setting. ( 27628826 )
2016
7
Satisfaction of patients with Peyronie's disease after plaque surgery and bovine pericardium graft. ( 27468940 )
2016
8
Re: Female Partners of Men with Peyronie's Disease Have Impaired Sexual Function, Satisfaction, and Mood, while Degree of Sexual Interference is Associated with Worse Outcomes. ( 27751478 )
2016
9
A prospective, randomized, single - blind study comparing intraplaque injection of thiocolchicine and verapamil in Peyronie's Disease: a pilot study. ( 24893912 )
2016
10
Re: An Analysis of Case Logs from American Urologists in the Treatment of Peyronie's Disease. ( 27186766 )
2016
11
Nonsurgical Interventions for Peyronie's Disease: Update as of 2016. ( 27574590 )
2016
12
Re: Outcomes of Surgical Management of Men with Peyronie's Disease with Hourglass Deformity. ( 27628824 )
2016
13
Injectable therapy for Peyronie's disease. ( 27298778 )
2016
14
Re: The Prevalence of Peyronie's Disease in the United States: AA Population-Based Study. ( 27628825 )
2016
15
Peyronie's disease: What's around the bend? ( 26941488 )
2016
16
The Prevalence of Peyronie's Disease in the United States: A Population-Based Study. ( 26907743 )
2016
17
--- ---Recent advances in managing Peyronie's disease. ( 27746896 )
2016
18
Re: Comparative Analysis of Tunical Plication vs. Intralesional Injection Therapy for Ventral Peyronie's Disease. ( 27186764 )
2016
19
Increased aquaporin 1 expression in the tunica albuginea of Peyronie's disease patients: an in vivo pilot study. ( 26972451 )
2016
20
Extracorporeal shock wave therapy (ESWT) in urology: a systematic review of outcome in Peyronie's disease, erectile dysfunction and chronic pelvic pain. ( 27108421 )
2016
21
Re: Outcomes of Surgical Management of Men with Peyronie's Disease with Hourglass Deformity. ( 27845111 )
2016
22
Nonsurgical treatment options in Peyronie's Disease: 2016 update. ( 27909612 )
2016
23
Peyronie's Disease: Intralesional Therapy and Surgical Intervention. ( 27432377 )
2016
24
The Outcome of Multiple Slit on Plaque with Plication Technique for the Treatment of Peyronie's Disease. ( 27169125 )
2016
25
Data vs Dogma in Peyronie's Disease. ( 27813380 )
2016
26
A review of surgical strategies for penile prosthesis implantation in patients with Peyronie's disease. ( 27298781 )
2016
27
Research highlights on stem cell therapy for the treatment of Peyronie's disease. ( 27298783 )
2016
28
Pro: does shockwave therapy have a place in the treatment of Peyronie's disease? ( 27298784 )
2016
29
Bicentric prospective evaluation of corporoplasty with porcine small intestinal submucosa (SIS) in patients with severe Peyronie's disease. ( 27864619 )
2016
30
Re: Topical Treatment for Acute Phase Peyronie's Disease Utilizing a New Gel, H-100: A Randomized, Prospective, Placebo-Controlled Pilot Study. ( 27186765 )
2016
31
Contemporary Review of Treatment Options for Peyronie's Disease. ( 26898900 )
2016
32
Results of SMSNA Survey Regarding Complications Following Intralesional Injection Therapy With Collagenase Clostridium Histolyticum for Peyronie's Disease. ( 27045265 )
2016
33
Grafting techniques for Peyronie's disease. ( 27298780 )
2016
34
Surgical treatment of Peyronie's disease with small intestinal submucosa graft patch. ( 27030055 )
2016
35
Re: A Meta-analysis of Extracorporeal Shock Wave Therapy for Peyronie's Disease. ( 27567204 )
2016
36
Alternative Splicing of IGF1 Gene as a Potential Factor in the Pathogenesis of Peyronie's Disease. ( 27107083 )
2016
37
Buccal mucosa is a promising graft in Peyronie's disease surgery. Our experience and a brief literature review on autologous grafting materials. ( 27377087 )
2016
38
Prevalence, psychological impact, and risk factors of erectile dysfunction in patients with Peyronie's disease: a retrospective analysis of 309 cases. ( 27486570 )
2016
39
Collagenase Clostridium Histolyticum for the Treatment of Peyronie's Disease: A 'Real World' Clinical Perspective. ( 27770352 )
2016
40
Role of extracorporeal shock wave therapy in management of Peyronie's disease: A preliminary report. ( 28057983 )
2016
41
Con: does shockwave therapy have a place in the treatment of Peyronie's disease? ( 27298785 )
2016
42
Plication procedures-excisional and incisional corporoplasty and imbrication for Peyronie's disease. ( 27298779 )
2016
43
Evidence-Based Management Guidelines on Peyronie's Disease. ( 27215686 )
2016
44
The Genetic Basis of Peyronie's Disease: A Review. ( 26955480 )
2016
45
Peyronie's Disease and Injectable Collagenase Clostridium Histolyticum: Safety, Efficacy and Improvements in Subjective Symptoms. ( 27211926 )
2016
46
Lengthening strategies for Peyronie's disease. ( 27298782 )
2016
47
Impact of Number of Cycles of Collagenase Clostridium Histolyticum on Outcomes in Patients with Peyronie's Disease. ( 27816605 )
2016
48
Re: Self-Report and Clinical Response to Peyronie's Disease Treatment: Peyronie's Disease Questionnaire Results from 2 Large Double-Blind, Randomized, Placebo-Controlled Phase 3 Studies. ( 27302808 )
2016
49
The Therapeutic Effects of Intracavernosal Plaque Excision in Peyronie's Disease: A None Grafting or Tunical Excising Procedure. ( 27308243 )
2016
50
Female Partners of Men With Peyronie's Disease Have Impaired Sexual Function, Satisfaction, and Mood, While Degree of Sexual Interference Is Associated With Worse Outcomes. ( 27209179 )
2016

Variations for Peyronie's Disease

Expression for Peyronie's Disease

Search GEO for disease gene expression data for Peyronie's Disease.

Pathways for Peyronie's Disease

Pathways related to Peyronie's Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.53 IFNA2 NOS2 SMAD3 TGFB1 TGFB2 TGFB3
2
Show member pathways
13.42 IFNA2 SMAD3 SMAD7 TGFB1 TGFB2 TGFB3
3
Show member pathways
13.23 IFNA2 NOS2 PDE5A TGFB1 TGFB2 TGFB3
4
Show member pathways
13.18 ACTG2 SMAD3 TGFB1 TGFB2 TGFB3
5
Show member pathways
12.84 ACTG2 NOS2 TGFB1 TGFB2 TGFB3
6
Show member pathways
12.76 ACTG2 TGFB1 TGFB2 TGFB3
7
Show member pathways
12.76 IFNA2 NOS2 SMAD3 TGFB1 TGFB2 TGFB3
8
Show member pathways
12.66 DCN TGFB1 TGFB2 TGFB3
9 12.6 NOS2 SMAD3 TGFB1 TGFB2 TGFB3
10
Show member pathways
12.53 SMAD3 TGFB1 TGFB2 TGFB3
11
Show member pathways
12.49 SMAD3 TGFB1 TGFB2 TGFB3
12
Show member pathways
12.43 SMAD3 TGFB1 TGFB2 TGFB3
13 12.38 SMAD3 TGFB1 TGFB2 TGFB3
14 12.37 SMAD3 TGFB1 TGFB2 TGFB3
15 12.31 SMAD3 TGFB1 TGFB2 TGFB3
16
Show member pathways
12.3 SMAD3 TGFB1 TGFB2 TGFB3
17
Show member pathways
12.25 TGFB1 TGFB2 TGFB3
18 12.21 DCN TGFB1 TGFB2
19
Show member pathways
12.2 SMAD3 SMAD7 TGFB1
20
Show member pathways
12.2 NOS2 TGFB1 TGFB2 TGFB3
21 12.18 SMAD3 TGFB1 TGFB2 TGFB3
22
Show member pathways
12.13 SMAD3 TGFB1 TGFB2
23
Show member pathways
12.12 TGFB1 TGFB2 TGFB3
24 12.08 IFNA2 NOS2 TGFB1 TGFB2 TGFB3
25
Show member pathways
12.05 SMAD3 TGFB1 TGFB2 TGFB3
26
Show member pathways
12.03 SMAD3 TGFB1 TGFB2 TGFB3
27 12 SMAD3 SMAD7 TGFB1
28 11.94 NOS2 SMAD3 TGFB1 TGFB2 TGFB3
29
Show member pathways
11.87 SMAD3 TGFB1 TGFB2 TGFB3
30 11.84 SMAD3 TGFB1 TGFB2 TGFB3
31 11.84 SMAD3 SMAD7 TGFB1 TGFB2 TGFB3
32 11.82 TGFB1 TGFB2 TGFB3
33 11.82 NOS2 TGFB1 TGFB2 TGFB3
34 11.81 DCN TGFB1 TGFB2 TGFB3
35 11.8 TGFB1 TGFB2 TGFB3
36
Show member pathways
11.72 TGFB1 TGFB2 TGFB3
37 11.71 SMAD3 SMAD7 TGFB1
38
Show member pathways
11.69 SMAD3 SMAD7 TGFB1
39 11.62 TGFB1 TGFB2 TGFB3
40 11.62 NOS2 TGFB1 TGFB2 TGFB3
41 11.59 SMAD3 SMAD7 TGFB1
42 11.54 TGFB1 TGFB2 TGFB3
43 11.53 ACTG2 SMAD3 TGFB1 TGFB2 TGFB3
44 11.52 NOS2 SMAD3 TGFB1
45 11.51 DCN TGFB1 TGFB2 TGFB3
46 11.49 TGFB1 TGFB2 TGFB3
47
Show member pathways
11.44 SMAD3 TGFB1 TGFB2
48
Show member pathways
11.39 TGFB1 TGFB2 TGFB3
49 11.38 SMAD3 SMAD7 TGFB1 TGFB3
50 11.35 SMAD3 SMAD7 TGFB1 TGFB2 TGFB3

GO Terms for Peyronie's Disease

Cellular components related to Peyronie's Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.63 ACTG2 DCN IFNA2 TGFB1 TGFB2 TGFB3
2 extracellular matrix GO:0031012 9.26 DCN TGFB1 TGFB2 TGFB3
3 platelet alpha granule lumen GO:0031093 8.8 TGFB1 TGFB2 TGFB3

Biological processes related to Peyronie's Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.98 ACTG2 SMAD3 TGFB1 TGFB2
2 regulation of apoptotic process GO:0042981 9.91 TGFB1 TGFB2 TGFB3
3 negative regulation of gene expression GO:0010629 9.9 IFNA2 NOS2 TGFB1 TGFB2
4 aging GO:0007568 9.89 DCN TGFB1 TGFB3
5 cell cycle arrest GO:0007050 9.87 SMAD3 TGFB1 TGFB2
6 platelet degranulation GO:0002576 9.87 TGFB1 TGFB2 TGFB3
7 negative regulation of cell growth GO:0030308 9.86 SMAD3 TGFB1 TGFB2
8 cellular response to transforming growth factor beta stimulus GO:0071560 9.84 SMAD3 SMAD7 TGFB1
9 inner ear development GO:0048839 9.84 TGFB1 TGFB2 TGFB3
10 cell growth GO:0016049 9.83 TGFB1 TGFB2 TGFB3
11 BMP signaling pathway GO:0030509 9.83 SMAD7 TGFB1 TGFB2 TGFB3
12 cell development GO:0048468 9.81 TGFB1 TGFB2 TGFB3
13 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.8 TGFB1 TGFB2 TGFB3
14 positive regulation of cell division GO:0051781 9.8 TGFB1 TGFB2 TGFB3
15 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.8 SMAD3 SMAD7 TGFB1 TGFB3
16 response to hypoxia GO:0001666 9.8 NOS2 SMAD3 TGFB1 TGFB2 TGFB3
17 ureteric bud development GO:0001657 9.79 SMAD3 SMAD7 TGFB1
18 extrinsic apoptotic signaling pathway GO:0097191 9.79 SMAD3 TGFB1 TGFB2
19 response to progesterone GO:0032570 9.78 TGFB1 TGFB2 TGFB3
20 positive regulation of protein secretion GO:0050714 9.77 TGFB1 TGFB2 TGFB3
21 positive regulation of bone mineralization GO:0030501 9.76 SMAD3 TGFB1 TGFB3
22 SMAD protein signal transduction GO:0060395 9.76 SMAD3 TGFB1 TGFB2 TGFB3
23 epithelial to mesenchymal transition GO:0001837 9.73 TGFB1 TGFB2
24 negative regulation of T cell proliferation GO:0042130 9.73 PDE5A TGFB1
25 digestive tract development GO:0048565 9.73 TGFB1 TGFB3
26 odontogenesis GO:0042476 9.73 TGFB2 TGFB3
27 negative regulation of protein catabolic process GO:0042177 9.73 NOS2 SMAD3
28 ventricular septum morphogenesis GO:0060412 9.72 SMAD7 TGFB2
29 endoderm development GO:0007492 9.72 SMAD3 TGFB1
30 mammary gland development GO:0030879 9.72 TGFB1 TGFB3
31 negative regulation of mitotic cell cycle GO:0045930 9.72 SMAD3 TGFB1
32 face morphogenesis GO:0060325 9.72 TGFB1 TGFB2 TGFB3
33 positive regulation of collagen biosynthetic process GO:0032967 9.71 TGFB1 TGFB3
34 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.71 SMAD7 TGFB1
35 positive regulation of protein localization to nucleus GO:1900182 9.71 TGFB1 TGFB2
36 positive regulation of pri-miRNA transcription from RNA polymerase II promoter GO:1902895 9.71 SMAD3 TGFB1
37 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.71 SMAD3 SMAD7 TGFB1
38 negative regulation of DNA replication GO:0008156 9.7 TGFB1 TGFB3
39 negative regulation of immune response GO:0050777 9.69 TGFB1 TGFB2
40 pathway-restricted SMAD protein phosphorylation GO:0060389 9.69 SMAD7 TGFB1 TGFB2
41 lens fiber cell differentiation GO:0070306 9.68 SMAD3 TGFB1
42 positive regulation of SMAD protein import into nucleus GO:0060391 9.68 TGFB1 TGFB3
43 SMAD protein complex assembly GO:0007183 9.68 SMAD3 TGFB1
44 heart valve morphogenesis GO:0003179 9.67 TGFB1 TGFB2
45 regulation of striated muscle tissue development GO:0016202 9.67 SMAD3 TGFB1
46 ossification involved in bone remodeling GO:0043932 9.65 TGFB1 TGFB3
47 frontal suture morphogenesis GO:0060364 9.65 TGFB1 TGFB3
48 regulation of transforming growth factor beta2 production GO:0032909 9.65 SMAD3 TGFB2
49 salivary gland morphogenesis GO:0007435 9.65 TGFB1 TGFB2 TGFB3
50 regulation of binding GO:0051098 9.64 SMAD3 TGFB1

Molecular functions related to Peyronie's Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.71 SMAD3 TGFB1 TGFB2 TGFB3
2 cytokine activity GO:0005125 9.62 IFNA2 TGFB1 TGFB2 TGFB3
3 growth factor activity GO:0008083 9.61 TGFB1 TGFB2 TGFB3
4 collagen binding GO:0005518 9.54 DCN SMAD3 SMAD7
5 type I transforming growth factor beta receptor binding GO:0034713 9.43 SMAD7 TGFB1 TGFB3
6 type II transforming growth factor beta receptor binding GO:0005114 9.33 TGFB1 TGFB2 TGFB3
7 transforming growth factor beta receptor binding GO:0005160 9.26 SMAD3 TGFB1 TGFB2 TGFB3
8 type III transforming growth factor beta receptor binding GO:0034714 8.8 TGFB1 TGFB2 TGFB3

Sources for Peyronie's Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....